# Official Website: Bioparin

**Type:** source
**Status:** Useful
**Confidence:** Low
**Source Type:** Official Website
**URL:** Unknown (search: Bioparin University of Utah)
**Publisher:** Bioparin
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

A confirmed public website URL for Bioparin was not identified in the source material; the legacy intake record suggested searching "Bioparin University of Utah" to find current web presence. Bioparin is a University of Utah spinout, founded around 2023, working on synthetic heparin production. The company has received STTR federal funding. The scientific context for the venture — heparin supply chain fragility, the 2008 contamination crisis, and the technical challenge of synthetic polysaccharide biosynthesis — is well-documented in public sources. Claims specific to Bioparin's approach, team, and progress derive from U of U research spinout records and the STTR funding record.

## Useful Claims

- Bioparin is a University of Utah spinout, founded around 2023.
- The company has received STTR federal funding (early-stage non-dilutive).
- Mission: produce heparin synthetically rather than extracting it from pig intestines.
- Location: Salt Lake City, UT.
- Stage: early; no major VC round publicly identified.

## Reliability Notes

Official website not confirmed. The 2008 heparin contamination crisis and the global supply chain context are well-documented through FDA public records and academic literature. Claims about Bioparin specifically — team, approach, and STTR phase — are low-confidence until confirmed from a primary source. The venture page notes this URL gap as an open question.

## Related Pages

- [Bioparin](bioparin.md)